Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 801,435
  • Shares Outstanding, K 132,250
  • Annual Sales, $ 60,000 K
  • Annual Income, $ -143,660 K
  • 36-Month Beta 2.20
  • Price/Sales 13.62
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.61 +7.93%
on 11/21/17
6.55 -7.48%
on 12/04/17
-0.12 (-1.94%)
since 11/10/17
3-Month
4.80 +26.25%
on 11/03/17
8.28 -26.81%
on 10/02/17
-0.69 (-10.22%)
since 09/12/17
52-Week
1.53 +296.08%
on 12/22/16
8.84 -31.45%
on 08/31/17
+4.30 (+244.32%)
since 12/12/16

Most Recent Stories

More News
Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Office Depot, Inc. (NASDAQ:ODP),...

CDR : 6.11 (-0.16%)
CRR : 10.11 (-0.30%)
IMGN : 6.06 (-1.94%)
ODP : 3.28 (-2.96%)
CNSL : 12.42 (-6.48%)
CPRX : 4.17 (-0.71%)
Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?

ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.

MRK : 57.07 (+1.30%)
LLY : 86.71 (+0.05%)
IMGN : 6.06 (-1.94%)
RHHBY : 30.3400 (+0.26%)
Biotechnology and Oncology Markets Have Positive Projections

According to a report by Grand View Research (GVR), the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine...

RGBP : 0.0712 (-3.39%)
IDRA : 1.91 (-4.02%)
OMED : 3.92 (-15.52%)
IMGN : 6.06 (-1.94%)
INO : 4.25 (-5.56%)
Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

If you want a Stock Review on IMGN, INCY, INFI, or INSM then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Ahead of today's trading session, DailyStockTracker.com...

IMGN : 6.06 (-1.94%)
INCY : 95.40 (-1.90%)
INFI : 1.82 (-6.19%)
INSM : 29.61 (+0.82%)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

JAZZ : 140.55 (+0.39%)
EBS : 45.48 (+3.08%)
IMGN : 6.06 (-1.94%)
EXEL : 26.84 (+1.59%)
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by...

IMGN : 6.06 (-1.94%)
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up

ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.

LGND : 135.80 (+0.55%)
MRK : 57.07 (+1.30%)
IMGN : 6.06 (-1.94%)
RHHBY : 30.3400 (+0.26%)
ImmunoGen (IMGN) Reports Wider-than-Expected Q3 Loss

ImmunoGen posted wider-than-expected loss in the third quarter of 2017. Revenues also missed expectations considerably.

IMGN : 6.06 (-1.94%)
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results

--$100+ Million Follow-on Financing Provides Two-year Operating Runway

IMGN : 6.06 (-1.94%)
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?

ImmunoGen (IMGN) favorable Zacks Rank and positive ESP enhance its potential for a beat.

IMGN : 6.06 (-1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 6.33
1st Resistance Point 6.20
Last Price 6.06
1st Support Level 5.91
2nd Support Level 5.75

See More

52-Week High 8.84
Last Price 6.06
Fibonacci 61.8% 6.05
Fibonacci 50% 5.18
Fibonacci 38.2% 4.32
52-Week Low 1.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.